Some Breast Cancer Patients May Not Need Node Dissection

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 4
Volume 6
Issue 4

BERN, Switzerland--A study of 1,619 breast cancer patients has identified a population subset with a very low incidence of lymph node metastases in whom axillary lymph node dissection might be omitted, Andreas Barth, MD, told Oncology News International.

BERN, Switzerland--A study of 1,619 breast cancer patients has identifieda population subset with a very low incidence of lymph node metastasesin whom axillary lymph node dissection might be omitted, Andreas Barth,MD, told Oncology News International.

This series of patients was comprised of those with T1-T4 breast cancerwho underwent level I/II axillary dissection between 1979 and 1995 at TheBreast Center, Van Nuys, Calif. Analysis of 11 clinical/pathological factorsshowed that patients with nonpalpable, non-high grade tumors of less than10 mm, with no lymph-vascular space involvement had an incidence of lymphnode metastases of only 3%.

"In these patients, a lymph node dissection could be omitted, especiallyif they are postmenopausal and ER positive," said Dr. Barth, of theInstitute of Medical Oncology, Bern, Switzerland. Dr. Barth worked on thestudy under Dr. Melvin Silverstein during a fellowship at Van Nuys, andpresented the data at the San Antonio Breast Cancer Symposium.

He pointed out that this population subset comprises only about 7% ofall breast cancer patients, "so it doesn't solve the problem for about93%, and that's where newer techniques, like the sentinel lymph node biopsy,might come in."

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.